Skip to content

Citius Oncology, Inc. CTOR Interest Expense, Nonoperating

Interest Expense, Nonoperating at other companies

CTO
Citius Oncology, Inc.CTOR
$33.03K
Spectral AI, Inc. logo
Spectral AI, Inc.MDAI
$258K+1,190%
XTI Aerospace, Inc. logo
XTI Aerospace, Inc.XTIA
$154K-29.0%
Cal-Maine Foods logo
Cal-Maine FoodsCALM
$153K+11.5%
Dakota Gold logo
Dakota GoldDC
$34.37K
Evommune
 logo
Evommune EVMN
$25.8K-72.9%

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s interest expense, nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s interest expense, nonoperating?
Citius Oncology, Inc. (CTOR) reported interest expense, nonoperating of $33.03K in Q1 2026.
What does interest expense, nonoperating mean?
Represents the costs incurred from borrowing funds, excluding any interest expenses directly tied to core operations. It highlights the company's debt burden and the impact of its capital structure on overall financial performance.